search
Back to results

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Primary Purpose

Myelodysplastic Syndromes

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Magrolimab
Azacitidine
Placebo
Sponsored by
Gilead Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myelodysplastic Syndromes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk.
  • Adequate performance status and hematological, liver, and kidney function

Key Exclusion Criteria:

  • Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor
  • Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents
  • Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R
  • Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year
  • Contraindications to azacitidine
  • Clinical suspicion of active central nervous system (CNS) involvement by MDS
  • Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history
  • Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening
  • Pregnancy or active breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Sites / Locations

  • University of Alabama Birmingham
  • University of Arkansas for Medical Sciences IRB
  • City of Hope
  • UC San Diego Moores Cancer Center
  • UCLA Ronald Reagan Medical Center
  • UC Irvine Health
  • Stanford Cancer Institute
  • University of California, Davis Comprehensive Cancer Center
  • University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center
  • Moffitt Cancer Center
  • Winship Cancer Institute
  • Northwestern Memorial Hospital
  • The University of Chicago Medical Center
  • University of Kansas Clinical Research Center
  • Tulane Medical Center
  • University of Maryland, Greenebaum Comprehensive Cancer Center
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
  • Massachusetts General Hospital
  • Beth Israel Deaconess Medical Center
  • Dana Farber Cancer Institute (DFCI)
  • University of Michigan Medical School
  • University of Minnesota Medical Center, Fairview
  • Mid America Division, Inc.
  • Washington University School of Medicine - Siteman Cancer Center
  • Roswell Park Cancer Institute
  • Weill Cornell Medicine-New York Presbyterian Hospital
  • Mount Sinai Health System
  • Columbia University Medical Center - Herbert Irving Pavilion
  • Memorial Sloan Kettering Cancer Center
  • University of North Carolina at Chapel Hill
  • DUHS Duke Cancer Center
  • The Ohio State University Wexner Medical Center / James Cancer Hospital
  • University of Oklahoma Health Sciences Center
  • Oregon Health & Science University Pharmacy Services
  • Hospital of the University of Pennsylvania
  • Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization
  • Fox Chase Cancer Center
  • Prisma Health Cancer Center
  • Tennessee Oncology, PLLC
  • UT Southwestern Medical Center
  • Texas Oncology - Baylor Charles A. Simmons Cancer Center
  • Baylor College of Medicine
  • The University of Texas MD Anderson Cancer Center
  • Huntsman Cancer Institute/University of Utah
  • Seattle Cancer Care Alliance
  • Swedish Cancer Institute
  • Froedtert Hospital & the Medical College of Wisconsin
  • Gosford Hospital
  • Prince of Wales Hospital
  • Royal North Shore Hospital
  • Westmead Hospital
  • Icon Cancer Foundation
  • Royal Adelaide Hospital
  • Flinders Medical Center
  • Royal Hobart Hospital
  • Eastern Health
  • Monash Medical Centre
  • Peninsula Private Hospital
  • Barwon Health, University Hospital Geelong
  • Cabrini Hospital Malvern
  • The Alfred Hospital
  • Royal Melbourne Hospital
  • Sir Charles Gairdner Hospital
  • Uniklinikum Salzburg
  • Hanusch kranhenkaus, 3. Medizinische Abteilung
  • ZNA Middelheim
  • ULB Hopital Erasme
  • Cliniques Universitaires Saint-Luc
  • UZ Brussel
  • UZ Leuven
  • AZ Turnhout, Campus St. Elisabeth
  • Chu Ucl Namur Site Godinne
  • Tom Baker Cancer Centre
  • QEII Health Sciences Centre
  • Eastern Regional Health Authority
  • University Health Network
  • Fakultni nemocnice Olomouc, Hemato-onkologicka klinika
  • Fakultni nemocnice Ostrava, Klinika hemato-onkologicka
  • Helsinki University Central Hospital
  • Oulu University Hospital
  • CHU Amiens-Picardie
  • Hopital Henri Mondor
  • CHU de Grenoble Alpes
  • Institut Paoli Calmettes
  • Hopital Saint Eloi
  • CHU de Nantes
  • CHU de Nice-l Archet
  • Hopital Saint Louis
  • Institut Gustave Roussy
  • Hopital Haut-Leveque
  • Centre Hospitalier Lyon Sud
  • CHU de Poitiers - Hopital de la Miletrie
  • CHU de Rennes- Hopital Pontchaillou
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz, III. Medizinische Klinik und Poliklinik
  • Universitatsklinikum Carl Gustav Carus
  • Marien hospital, klinik fur onkologie, hamatologie und palliavmedizin
  • Universitatsklinikum Essen
  • Universitat Leipzig
  • Robert-Bosch-Krankenhaus, GmBH, Hamatologie, Onkologie und Palliativmedizin
  • Hong Kong Sanatorium & Hospital
  • Princess Margaret Hospital
  • Queen Mary Hospital
  • The Chinese University of Hong Kong, Prince of Wales Hospital
  • Tuen Mun Hospital
  • Semmelweis Egyetem Belgyógyászati és Hematológiai Kilnika
  • Debreceni Egyetem Klinikai Központ
  • Petz Aladar Egyetemi Oktato Korhaz II. Belgyogyaszat - Hematologial Osztaly
  • Kaposi Mor Teaching Hospital
  • Bács-Kiskun Megyei Kórház
  • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
  • University of Pecs
  • Szent Borbála Hospital
  • SC Ematologica- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo
  • U.O Ematologica- ASST degli Spedali Civili di Brescia
  • Azienda Ospedaliero-Universitaria Careggi
  • U.O.C Ematologia - Dipartimento di Medicina Interna, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
  • U.O di Ematologia, Ospedale San Gerardo- ASST Monza
  • S. C. Ematologia Azienda Ospedaliero - Universitaria Maggiore Della Carita
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
  • SC di Oncoematologia - Azienda Ospedaliera Santa Maria
  • SC Ematologica, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi
  • University Medical Center Groningen
  • Medisch Centrum Leeuwarden
  • Christchurch Hospital
  • Southern District Health Board
  • Auckland City Hospital
  • Waikato Hospital
  • Midcentral District Health Board
  • Haukeland Universitetssjukehus, seksjon for blodsjukdommar- klinisk studieteam
  • Akershus University Hospital
  • Oslo University Hospital
  • Stavanger universitetssjukehus
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Hematologii
  • Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
  • Centro Clinico Academico de Braga, Hospital de Braga, E.P.E
  • Champalimaud Foundation
  • Hospital da Luz
  • Centro Hospitalar Universitario Sao Joao. E.P.E
  • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
  • Centro Hospitalar Vila Nova de Gaia/Espinho
  • Area Sanitaria de Santiago de Compostela y Barbanza. Complejo Hospitalario Universitario de SantiagoD
  • OSI Araba, Hospital Universitario de Alava, Hospital Txagorritxu
  • Hospital del Mar
  • Hospital Universitari Vall D'Hebron
  • Institut Catala d'Oncologia Girona
  • Institut Catala d'Oncologia, Hospital Duran i Reynals
  • MD Anderson Cancer Center Madrid
  • Hospital Universitario Fundacion Jimenez Diaz
  • Hospital Universitario La Paz, Edificio General, 6 Planta. Despacho de Hematologia
  • Hospital Universitario Quironsalud Madrid. Servico de Hematologica y Hemoterapia
  • Hospital Regional Universitario de Malaga
  • Centro Hospitalar Universitario Sao Joao
  • Complejo Asistencial Universitario de Salamanca- Hospital Clinico Universitario de Salamanca
  • Hospital Universitario Virgen del Rocio
  • Hospital Clinico Universitario de Valencia
  • Istituto Oncologico Della Svizzera Italiana- IOSI, EOC, Clinica di Ematologia
  • University of Bern
  • Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie
  • Hematoloji Bilim Dali, Yenimahalle
  • Gazi Universitesi Tip Fakultesi
  • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
  • Dokuz Eylul Universitesi Tip Fakultesi Onkoloji Enstitusu
  • Mersin University Medical
  • Tekirdag Namik Kemal Universitesi Tip Fakultesi
  • University Hospitals Birmingham NHS Foundation Trust
  • United Lincolnshire Hospital NHS Trust
  • Kent and Canterbury Hospital- East Kent Hospitals University NHS Foundation Trust
  • Oxford University Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Magrolimab + Azacitidine

Control Arm (Placebo + Azacitidine)

Arm Description

Participants will receive the following magrolimab and azacitidine dosing regimens: Magrolimab: Magrolimab Priming Dose: 1 mg/kg on Days 1 and 4 15 mg/kg on Day 8 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Magrolimab Maintenance Dose: 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle

Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitadine: Placebo Priming Dose: 1 mg/kg on Days 1 and 4 15 mg/kg on Day 8 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Placebo Maintenance Dose: 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle

Outcomes

Primary Outcome Measures

Proportion of Participants with Complete Remission (CR)
The CR rate is the proportion of participants who reach morphologic CR based on Investigator-assessed International Working Group (IWG) 2006 Myelodysplastic Syndrome (MDS) criteria prior to initiation of any new MDS therapy including stem cell therapy (SCT).
Overall Survival (OS)
OS is defined as the length measured from randomization to the date of death from any cause.

Secondary Outcome Measures

Duration of CR
The duration of CR is measured from the time measurement criteria are first met for CR to the first date of relapse or death, whichever occurs earlier. Those who are not observed to relapse or die will be censored at their last response assessment date with evidence of no relapse. Participants who achieve a CR and then proceed to an allogeneic SCT will continue to be followed for the response assessment post transplant, will be included in the analysis of duration of CR, and will not be censored at the time of transplant.
Objective Response Rate (ORR)
ORR is the proportion of participants who reach objective response including CR, partial response (PR), marrow CR, or hematologic improvement per IWG 2006 MDS criteria prior to initiation of any new anticancer therapy for MDS, including SCT.
Duration of Response (DOR)
DOR is measured from the time measurement criteria are first met for objective response to the first date of relapse, disease progression or death, whichever occurs earlier. Those who are not observed to relapse, disease progress or die will be censored at their last response assessment date with evidence of no relapse/no disease progression. Participants who achieve a response and then proceed to an allogeneic SCT will continue to be followed for the DOR post transplant, will be included in the analysis of DOR, and will not be censored at the time of transplant.
Red Blood Cell (RBC) Transfusion Independence Rate
The RBC transfusion independence rate is the proportion of participants who have a 56-day or longer period with no RBC transfusions at any time between randomization and initiation of any new anticancer therapy, including SCT, among all participants who are RBC transfusion-dependent at baseline.
Progression Free Survival (PFS)
The length of PFS is defined as the time from randomization to the date of documented disease progression (including treatment failure by IWG criteria or relapse after PR/CR), or death from any cause, whichever occurs first. Those who are not observed to have one of these events will be censored at their last response assessment date with evidence of no disease progression/relapse.
Event Free Survival (EFS)
The length of EFS is defined as the time from randomization to transformation to acute myeloid leukemia (AML) or death from any cause, whichever occurs first. Participants who are not observed to have one of these events during the study will be censored at their last response assessment date with evidence of no transformation to AML.
Minimal Residual Disease (MRD)-negative Response Rate
The MRD-negative response rate is defined as the proportion of participants who achieve a morphologic CR or marrow CR based on Investigator-assessed IWG criteria and reach MRD-negative disease status prior to initiation of any new anticancer therapy, including SCT. MRD-negative disease status will be assessed using a multiparameter flow cytometry-based assay performed by a central laboratory.
Time to Transformation to AML
Time to transformation to AML is defined as the time from randomization to the collection date of bone marrow sample leading to documented AML diagnosis. Participants who are not observed to have transformation to AML will be censored at their last response assessment date with evidence of no AML diagnosis.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Serum Concentration of Magrolimab
Pretreatment assessments for the initial dose may be collected up to 72 hours before administration of study treatment; thereafter, pretreatment assessments are to be collected within 24 hours prior to study treatment administration.
Anti-magrolimab Antibody Positivity Occurrence Rate
Functional Assessment of Cancer Therapy-Anemia (FACT-Anemia) Response Rate
The FACT-Anemia response rate is defined as the proportion of participants who showed clinically meaningful improvement in health-related quality of life (HRQoL) based on the score from the FACT-Anemia instrument prior to initiation of any new anticancer therapy for MDS, including SCT. The FACT-Anemia instrument consists of 5 subscales, including physical well-being, emotional well-being, functional well-being, social well-being, and anemia symptoms. Each subscale measures items on a 5-point Likert scale from 0 to 4, where 0 = not at all and 4 = very much.

Full Information

First Posted
March 11, 2020
Last Updated
September 21, 2023
Sponsor
Gilead Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT04313881
Brief Title
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Acronym
ENHANCE
Official Title
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Terminated
Why Stopped
Study discontinued due to futility based on a planned analysis
Study Start Date
September 9, 2020 (Actual)
Primary Completion Date
July 18, 2023 (Actual)
Study Completion Date
September 4, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gilead Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelodysplastic Syndromes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
539 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Magrolimab + Azacitidine
Arm Type
Experimental
Arm Description
Participants will receive the following magrolimab and azacitidine dosing regimens: Magrolimab: Magrolimab Priming Dose: 1 mg/kg on Days 1 and 4 15 mg/kg on Day 8 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Magrolimab Maintenance Dose: 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle
Arm Title
Control Arm (Placebo + Azacitidine)
Arm Type
Placebo Comparator
Arm Description
Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitadine: Placebo Priming Dose: 1 mg/kg on Days 1 and 4 15 mg/kg on Day 8 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50) Placebo Maintenance Dose: 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle
Intervention Type
Drug
Intervention Name(s)
Magrolimab
Other Intervention Name(s)
Hu5F9-G4, GS-4721
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Azacitidine
Intervention Description
Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo to match magrolimab administered intravenously
Primary Outcome Measure Information:
Title
Proportion of Participants with Complete Remission (CR)
Description
The CR rate is the proportion of participants who reach morphologic CR based on Investigator-assessed International Working Group (IWG) 2006 Myelodysplastic Syndrome (MDS) criteria prior to initiation of any new MDS therapy including stem cell therapy (SCT).
Time Frame
Up to 24 months
Title
Overall Survival (OS)
Description
OS is defined as the length measured from randomization to the date of death from any cause.
Time Frame
Up to 5 years
Secondary Outcome Measure Information:
Title
Duration of CR
Description
The duration of CR is measured from the time measurement criteria are first met for CR to the first date of relapse or death, whichever occurs earlier. Those who are not observed to relapse or die will be censored at their last response assessment date with evidence of no relapse. Participants who achieve a CR and then proceed to an allogeneic SCT will continue to be followed for the response assessment post transplant, will be included in the analysis of duration of CR, and will not be censored at the time of transplant.
Time Frame
Up to 5 years
Title
Objective Response Rate (ORR)
Description
ORR is the proportion of participants who reach objective response including CR, partial response (PR), marrow CR, or hematologic improvement per IWG 2006 MDS criteria prior to initiation of any new anticancer therapy for MDS, including SCT.
Time Frame
Up to 5 years
Title
Duration of Response (DOR)
Description
DOR is measured from the time measurement criteria are first met for objective response to the first date of relapse, disease progression or death, whichever occurs earlier. Those who are not observed to relapse, disease progress or die will be censored at their last response assessment date with evidence of no relapse/no disease progression. Participants who achieve a response and then proceed to an allogeneic SCT will continue to be followed for the DOR post transplant, will be included in the analysis of DOR, and will not be censored at the time of transplant.
Time Frame
Up to 5 years
Title
Red Blood Cell (RBC) Transfusion Independence Rate
Description
The RBC transfusion independence rate is the proportion of participants who have a 56-day or longer period with no RBC transfusions at any time between randomization and initiation of any new anticancer therapy, including SCT, among all participants who are RBC transfusion-dependent at baseline.
Time Frame
Up to 5 years
Title
Progression Free Survival (PFS)
Description
The length of PFS is defined as the time from randomization to the date of documented disease progression (including treatment failure by IWG criteria or relapse after PR/CR), or death from any cause, whichever occurs first. Those who are not observed to have one of these events will be censored at their last response assessment date with evidence of no disease progression/relapse.
Time Frame
Up to 5 years
Title
Event Free Survival (EFS)
Description
The length of EFS is defined as the time from randomization to transformation to acute myeloid leukemia (AML) or death from any cause, whichever occurs first. Participants who are not observed to have one of these events during the study will be censored at their last response assessment date with evidence of no transformation to AML.
Time Frame
Up to 5 years
Title
Minimal Residual Disease (MRD)-negative Response Rate
Description
The MRD-negative response rate is defined as the proportion of participants who achieve a morphologic CR or marrow CR based on Investigator-assessed IWG criteria and reach MRD-negative disease status prior to initiation of any new anticancer therapy, including SCT. MRD-negative disease status will be assessed using a multiparameter flow cytometry-based assay performed by a central laboratory.
Time Frame
Up to 5 years
Title
Time to Transformation to AML
Description
Time to transformation to AML is defined as the time from randomization to the collection date of bone marrow sample leading to documented AML diagnosis. Participants who are not observed to have transformation to AML will be censored at their last response assessment date with evidence of no AML diagnosis.
Time Frame
Up to 5 years
Title
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time Frame
Up to 5 years
Title
Serum Concentration of Magrolimab
Description
Pretreatment assessments for the initial dose may be collected up to 72 hours before administration of study treatment; thereafter, pretreatment assessments are to be collected within 24 hours prior to study treatment administration.
Time Frame
Up to 12 hours before administration of any treatment at Days 1, 8, 15, 22 of Cycle1; at Day 1 of Cycles 2, 3, 5, 7, 9, and 13, and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days
Title
Anti-magrolimab Antibody Positivity Occurrence Rate
Time Frame
Up to 72 hours before administration of any treatment at Day 1, Cycle 1; within 24 hours prior to any study drug administration at Day 1 of Cycles 2, 3, 5, 7, 10, and 13 and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days
Title
Functional Assessment of Cancer Therapy-Anemia (FACT-Anemia) Response Rate
Description
The FACT-Anemia response rate is defined as the proportion of participants who showed clinically meaningful improvement in health-related quality of life (HRQoL) based on the score from the FACT-Anemia instrument prior to initiation of any new anticancer therapy for MDS, including SCT. The FACT-Anemia instrument consists of 5 subscales, including physical well-being, emotional well-being, functional well-being, social well-being, and anemia symptoms. Each subscale measures items on a 5-point Likert scale from 0 to 4, where 0 = not at all and 4 = very much.
Time Frame
Up to 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk. Adequate performance status and hematological, liver, and kidney function Key Exclusion Criteria: Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year Contraindications to azacitidine Clinical suspicion of active central nervous system (CNS) involvement by MDS Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening Pregnancy or active breastfeeding Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilead Study Director
Organizational Affiliation
Gilead Sciences
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of Arkansas for Medical Sciences IRB
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
UC San Diego Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
UCLA Ronald Reagan Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
UC Irvine Health
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Stanford Cancer Institute
City
Palo Alto
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
University of California, Davis Comprehensive Cancer Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Winship Cancer Institute
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Northwestern Memorial Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
The University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
University of Kansas Clinical Research Center
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Facility Name
Tulane Medical Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
University of Maryland, Greenebaum Comprehensive Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Dana Farber Cancer Institute (DFCI)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
University of Michigan Medical School
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
University of Minnesota Medical Center, Fairview
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Mid America Division, Inc.
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64132
Country
United States
Facility Name
Washington University School of Medicine - Siteman Cancer Center
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Roswell Park Cancer Institute
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Facility Name
Weill Cornell Medicine-New York Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Mount Sinai Health System
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Columbia University Medical Center - Herbert Irving Pavilion
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
University of North Carolina at Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
DUHS Duke Cancer Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
The Ohio State University Wexner Medical Center / James Cancer Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
University of Oklahoma Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Oregon Health & Science University Pharmacy Services
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Facility Name
Prisma Health Cancer Center
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Tennessee Oncology, PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
39090
Country
United States
Facility Name
Texas Oncology - Baylor Charles A. Simmons Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Huntsman Cancer Institute/University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Facility Name
Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98019
Country
United States
Facility Name
Swedish Cancer Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
Froedtert Hospital & the Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Gosford Hospital
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
Prince of Wales Hospital
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Facility Name
Royal North Shore Hospital
City
St Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Icon Cancer Foundation
City
South Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Flinders Medical Center
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Facility Name
Royal Hobart Hospital
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
Facility Name
Eastern Health
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Monash Medical Centre
City
Clayton
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Facility Name
Peninsula Private Hospital
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Facility Name
Barwon Health, University Hospital Geelong
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
Facility Name
Cabrini Hospital Malvern
City
Malvern
State/Province
Victoria
ZIP/Postal Code
3144
Country
Australia
Facility Name
The Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Facility Name
Sir Charles Gairdner Hospital
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Uniklinikum Salzburg
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Hanusch kranhenkaus, 3. Medizinische Abteilung
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Facility Name
ZNA Middelheim
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Facility Name
ULB Hopital Erasme
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
UZ Brussel
City
Brussels
Country
Belgium
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
AZ Turnhout, Campus St. Elisabeth
City
Turnhout
ZIP/Postal Code
2300
Country
Belgium
Facility Name
Chu Ucl Namur Site Godinne
City
Yvoir-Godinne
ZIP/Postal Code
5530
Country
Belgium
Facility Name
Tom Baker Cancer Centre
City
Calgary
ZIP/Postal Code
T2N 4N2
Country
Canada
Facility Name
QEII Health Sciences Centre
City
Halifax
ZIP/Postal Code
B3H 2Y9
Country
Canada
Facility Name
Eastern Regional Health Authority
City
St. John's
ZIP/Postal Code
A1B 3V6
Country
Canada
Facility Name
University Health Network
City
Toronto
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Fakultni nemocnice Olomouc, Hemato-onkologicka klinika
City
Olomouc
ZIP/Postal Code
77520
Country
Czechia
Facility Name
Fakultni nemocnice Ostrava, Klinika hemato-onkologicka
City
Ostrava
ZIP/Postal Code
70852
Country
Czechia
Facility Name
Helsinki University Central Hospital
City
Helsinki
ZIP/Postal Code
00290
Country
Finland
Facility Name
Oulu University Hospital
City
Oulu
ZIP/Postal Code
90220
Country
Finland
Facility Name
CHU Amiens-Picardie
City
Amiens Cedex 1
ZIP/Postal Code
80054
Country
France
Facility Name
Hopital Henri Mondor
City
Creteil
ZIP/Postal Code
94010
Country
France
Facility Name
CHU de Grenoble Alpes
City
La Tronche
ZIP/Postal Code
38700
Country
France
Facility Name
Institut Paoli Calmettes
City
Marseille
Country
France
Facility Name
Hopital Saint Eloi
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
CHU de Nantes
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
CHU de Nice-l Archet
City
Nice
ZIP/Postal Code
6200
Country
France
Facility Name
Hopital Saint Louis
City
Paris
ZIP/Postal Code
75475
Country
France
Facility Name
Institut Gustave Roussy
City
Paris
ZIP/Postal Code
94805
Country
France
Facility Name
Hopital Haut-Leveque
City
Pessac Cedex
ZIP/Postal Code
33604
Country
France
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
CHU de Poitiers - Hopital de la Miletrie
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
CHU de Rennes- Hopital Pontchaillou
City
Rennes Cedex 9
ZIP/Postal Code
35033
Country
France
Facility Name
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, III. Medizinische Klinik und Poliklinik
City
Braunschweig
ZIP/Postal Code
38114
Country
Germany
Facility Name
Universitatsklinikum Carl Gustav Carus
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Marien hospital, klinik fur onkologie, hamatologie und palliavmedizin
City
Duesseldorf
Country
Germany
Facility Name
Universitatsklinikum Essen
City
Essen
ZIP/Postal Code
45122
Country
Germany
Facility Name
Universitat Leipzig
City
Leipzig
Country
Germany
Facility Name
Robert-Bosch-Krankenhaus, GmBH, Hamatologie, Onkologie und Palliativmedizin
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Facility Name
Hong Kong Sanatorium & Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Princess Margaret Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
The Chinese University of Hong Kong, Prince of Wales Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Tuen Mun Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Semmelweis Egyetem Belgyógyászati és Hematológiai Kilnika
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Debreceni Egyetem Klinikai Központ
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Petz Aladar Egyetemi Oktato Korhaz II. Belgyogyaszat - Hematologial Osztaly
City
Gyor
ZIP/Postal Code
9024
Country
Hungary
Facility Name
Kaposi Mor Teaching Hospital
City
Kaposvar
Country
Hungary
Facility Name
Bács-Kiskun Megyei Kórház
City
Kecskemet
ZIP/Postal Code
6000
Country
Hungary
Facility Name
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
City
Nyiregyhaza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
University of Pecs
City
Pecs
ZIP/Postal Code
7624
Country
Hungary
Facility Name
Szent Borbála Hospital
City
Tatabanya
ZIP/Postal Code
2800
Country
Hungary
Facility Name
SC Ematologica- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo
City
Alessandria
ZIP/Postal Code
15100
Country
Italy
Facility Name
U.O Ematologica- ASST degli Spedali Civili di Brescia
City
Brescia
Country
Italy
Facility Name
Azienda Ospedaliero-Universitaria Careggi
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
U.O.C Ematologia - Dipartimento di Medicina Interna, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
City
Milan
ZIP/Postal Code
20122
Country
Italy
Facility Name
U.O di Ematologia, Ospedale San Gerardo- ASST Monza
City
Monza
ZIP/Postal Code
20052
Country
Italy
Facility Name
S. C. Ematologia Azienda Ospedaliero - Universitaria Maggiore Della Carita
City
Novara
ZIP/Postal Code
28100
Country
Italy
Facility Name
Azienda Ospedaliera Ospedali Riuniti Marche Nord
City
Pesaro
ZIP/Postal Code
61100
Country
Italy
Facility Name
SC di Oncoematologia - Azienda Ospedaliera Santa Maria
City
Terni
ZIP/Postal Code
05100
Country
Italy
Facility Name
SC Ematologica, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi
City
Varese
ZIP/Postal Code
21100
Country
Italy
Facility Name
University Medical Center Groningen
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Facility Name
Christchurch Hospital
City
Christchurch
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Southern District Health Board
City
Dunedin
ZIP/Postal Code
9016
Country
New Zealand
Facility Name
Auckland City Hospital
City
Grafton
ZIP/Postal Code
1142
Country
New Zealand
Facility Name
Waikato Hospital
City
Hamilton
ZIP/Postal Code
3240
Country
New Zealand
Facility Name
Midcentral District Health Board
City
Palmerston North
ZIP/Postal Code
4414
Country
New Zealand
Facility Name
Haukeland Universitetssjukehus, seksjon for blodsjukdommar- klinisk studieteam
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Akershus University Hospital
City
Loerenskog
ZIP/Postal Code
1478
Country
Norway
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
0372
Country
Norway
Facility Name
Stavanger universitetssjukehus
City
Stavanger
ZIP/Postal Code
4068
Country
Norway
Facility Name
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Hematologii
City
Krakow
ZIP/Postal Code
31-501
Country
Poland
Facility Name
Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
City
Lublin
ZIP/Postal Code
20090
Country
Poland
Facility Name
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
City
Wroclaw
ZIP/Postal Code
50-367
Country
Poland
Facility Name
Centro Clinico Academico de Braga, Hospital de Braga, E.P.E
City
Braga
ZIP/Postal Code
4710
Country
Portugal
Facility Name
Champalimaud Foundation
City
Lisbon
ZIP/Postal Code
1400 - 038
Country
Portugal
Facility Name
Hospital da Luz
City
Lisbon
ZIP/Postal Code
1500-650
Country
Portugal
Facility Name
Centro Hospitalar Universitario Sao Joao. E.P.E
City
Porto
ZIP/Postal Code
4200 319
Country
Portugal
Facility Name
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Centro Hospitalar Vila Nova de Gaia/Espinho
City
Porto
ZIP/Postal Code
4430-999
Country
Portugal
Facility Name
Area Sanitaria de Santiago de Compostela y Barbanza. Complejo Hospitalario Universitario de SantiagoD
City
A Coruña
Country
Spain
Facility Name
OSI Araba, Hospital Universitario de Alava, Hospital Txagorritxu
City
Alava
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Universitari Vall D'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Institut Catala d'Oncologia Girona
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Institut Catala d'Oncologia, Hospital Duran i Reynals
City
L´Hospitalet de Llobregat
Country
Spain
Facility Name
MD Anderson Cancer Center Madrid
City
Madrid
ZIP/Postal Code
28033
Country
Spain
Facility Name
Hospital Universitario Fundacion Jimenez Diaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario La Paz, Edificio General, 6 Planta. Despacho de Hematologia
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Universitario Quironsalud Madrid. Servico de Hematologica y Hemoterapia
City
Madrid
Country
Spain
Facility Name
Hospital Regional Universitario de Malaga
City
Malaga
Country
Spain
Facility Name
Centro Hospitalar Universitario Sao Joao
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Complejo Asistencial Universitario de Salamanca- Hospital Clinico Universitario de Salamanca
City
Salamanca
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Istituto Oncologico Della Svizzera Italiana- IOSI, EOC, Clinica di Ematologia
City
Bellinzona
ZIP/Postal Code
6500
Country
Switzerland
Facility Name
University of Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
Facility Name
Hematoloji Bilim Dali, Yenimahalle
City
Ankara
ZIP/Postal Code
06200
Country
Turkey
Facility Name
Gazi Universitesi Tip Fakultesi
City
Ankara
ZIP/Postal Code
06560
Country
Turkey
Facility Name
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
City
Ankara
ZIP/Postal Code
06620
Country
Turkey
Facility Name
Dokuz Eylul Universitesi Tip Fakultesi Onkoloji Enstitusu
City
Inciralt
ZIP/Postal Code
35340
Country
Turkey
Facility Name
Mersin University Medical
City
Mersin
ZIP/Postal Code
33110
Country
Turkey
Facility Name
Tekirdag Namik Kemal Universitesi Tip Fakultesi
City
Tekirdag
ZIP/Postal Code
59100
Country
Turkey
Facility Name
University Hospitals Birmingham NHS Foundation Trust
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
United Lincolnshire Hospital NHS Trust
City
Boston
ZIP/Postal Code
PE21 9QS
Country
United Kingdom
Facility Name
Kent and Canterbury Hospital- East Kent Hospitals University NHS Foundation Trust
City
Canterbury
ZIP/Postal Code
CT1 3NG
Country
United Kingdom
Facility Name
Oxford University Hospitals NHS Foundation Trust
City
Oxford
ZIP/Postal Code
OX3 9DU
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.gileadclinicaltrials.com/study/?id=5F9009
Description
Gilead Clinical Trials Website

Learn more about this trial

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

We'll reach out to this number within 24 hrs